ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
EU FRP
Projektnummer
00.0218
Projekttitel
TARGETED GENE VECTOR: Targeted vectors for cancer gene therapy: receptor and transcriptional targeting of retroviral, lentiviral and adenoviral vectors.
Projekttitel Englisch
TARGETED GENE VECTOR: Targeted vectors for cancer gene therapy: receptor and transcriptional targeting of retroviral, lentiviral and adenoviral vectors.

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Schlüsselwörter
-
-
-
Anzeigen
Alternative Projektnummern
-
-
-
Anzeigen
Forschungsprogramme
-
-
-
Anzeigen
Kurzbeschreibung
-
-
-
Anzeigen
Weitere Hinweise und Angaben
-
-
-
Anzeigen
Partner und Internationale Organisationen
-
-
-
Anzeigen
Abstract
-
-
-
Anzeigen
Datenbankreferenzen
-
-
-
Anzeigen

Erfasste Texte


KategorieText
Schlüsselwörter
(Englisch)
Retroviral vectors; lentiviral vectors; adenoviral vectors
Alternative Projektnummern
(Englisch)
EU project number: QLK3-1999-00364
Forschungsprogramme
(Englisch)
EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'
Kurzbeschreibung
(Englisch)
See abstract
Weitere Hinweise und Angaben
(Englisch)
Full name of research-institution/enterprise:
Université de Genève
Département de Génétique et Microbiologie
CMU
Partner und Internationale Organisationen
(Englisch)
Coordinator: Université Pierre et Marie Curie (F)
Abstract
(Englisch)
Our laboratory developed lentiviral vectors, a new gene delivery system that offers great promises for human gene therwpy. Within the framework of this european project, we proposed to develop further and optimize lentiviral vector-based techniques for the transfer of genes into the liver. Over the last year we demonstrated that a so-called third-generation HIV-derived vector system can govern the efficient delivery, integration and stable expression of a transgene into primary human hepatocytes in the complete absence of cell division. We also showed that rat and mouse hepatocytes are significantly resistant to HIV vector-mediated transduction due to a block in the immediate-early phase of infection, an important shortcoming of rodent models for the preclinical assessment of this therapeutic tool. We finally described a methodology that allows very high rates of transduction through minimal in vitro manipulation, in which hepatocytes are kept in suspension and re-implanted within a few hours of harvest with a fully preserved engraftment potential. These results have immediate implications for the treatment of liver diseases via the transplantation of genetically modified hepatocytes, an approach that could be applied to a number of hereditary and acquired hepatic disorders.
Datenbankreferenzen
(Englisch)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 00.0218